Intraperitoneal α-Emitting Radioimmunotherapy with (211)At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work with α-particle–emitting (211)At, we performed a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer using (211)At conjugated to MX35, the an...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Nucl Med
Auteurs principaux: Hallqvist, Andreas, Bergmark, Karin, Bäck, Tom, Andersson, Håkan, Dahm-Kähler, Pernilla, Johansson, Mia, Lindegren, Sture, Jensen, Holger, Jacobsson, Lars, Hultborn, Ragnar, Palm, Stig, Albertsson, Per
Format: Artigo
Langue:Inglês
Publié: Society of Nuclear Medicine 2019
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681696/
https://ncbi.nlm.nih.gov/pubmed/30683761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.220384
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires